[Brain SPECT with 123I-lisuride in patients with Parkinson's disease and controls].
The goal was to visualize cerebral dopamine-D2 receptors in 6 patients with Parkinson's disease and in 3 healthy controls using iodine-123-Lisuride-SPECT. In addition, we performed receptor-replacement studies using 123I-Lisuride and cold Lisuride as competitive ligands. The highest uptake of 123I-Lisuride was observed in the striatum, a region with known high dopamine receptor density. In two patients premedication with cold Lisuride displaced 123I-Lisuride from the dopamine receptor. 123I-Lisuride is valuable as a radiotracer in cerebral dopamine-D2 receptor scintigraphy. Whether or not it is possible to determine dynamic changes of dopamine receptor density or function by receptor replacement studies needs further evaluation in larger patient populations.
Hierholzer
J
J
Strahlenklinik und Poliklinik, Virchow Klinikum der Humboldt-Universität zu Berlin, FRG.
Cordes
M
M
Schelosky
L
L
Richter
W
W
Schrag
A
A
Poewe
W
W
Schulze
P E
PE
Semmler
W
W
Eichstädt
H
H
Felix
R
R
D000328:Adult; D000368:Aged; D001667:Binding, Competitive; D001921:Brain / Q000000981:diagnostic imaging* / Q000378:metabolism; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D008090:Lisuride / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D012016:Reference Values; D015899:Tomography, Emission-Computed, Single-Photon
D007457:Iodine Radioisotopes; D017448:Receptors, Dopamine D2; D008090:Lisuride
Hirn-SPECT mit 123I-Lisurid bei Morbus-Parkinson-Patienten und Kontrollen.